No Data
No Data
No Data
No Data
No Data
Solid Earnings May Not Tell The Whole Story For Nanjing Vishee Medical Technology (SHSE:688580)
Nanjing Vishee Medical Technology Co., Ltd's (SHSE:688580) robust recent earnings didn't do much to move the stock. We think this is due to investors looking beyond the statutory profits and being co
Simply Wall St19:10 ET
Weiss Healthcare (688580.SH) reported first-quarter results, net profit of 21.7532 million yuan, a year-on-year decrease of 27.69%
Weiss Healthcare (688580.SH) released its report for the first quarter of 2024. The company achieved operating revenue during the reporting period...
Zhitong FinanceApr 25 05:26 ET
Weiss Healthcare (688580.SH): A total cost of 13.107 million yuan to buy back 0.3467% of the shares
Gelonghui, April 1 | Weisi Healthcare (688580.SH) announced that as of March 31, 2024, the company had repurchased a total of 237,893 shares of the company through centralized bidding transactions through the Shanghai Stock Exchange, accounting for 0.3467% of the company's total share capital. The highest price of the repurchase transaction was 65.88 yuan/share, the lowest price was 41.23 yuan/share, and the total amount of capital paid was RMB 13,107,011.20 (excluding transaction fees such as stamp duty and transaction fees).
Gelonghui FinanceApr 1 08:31 ET
Nanjing Vishee Medical Technology Co., Ltd (SHSE:688580) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?
With its stock down 22% over the past three months, it is easy to disregard Nanjing Vishee Medical Technology (SHSE:688580). But if you pay close attention, you might find that its key financial ind
Simply Wall StMar 27 21:25 ET
Weiss Healthcare (688580.SH): No implantable neuromodulation products are currently being developed or sold
Gelonghui, March 11 | Weiss Healthcare (688580.SH) said on the investor interactive platform, according to the World Neuromodulation Society's definition of “neuroregulation” — that is, in the field of combining technology, medical treatment, and bioengineering technology, signals are transmitted to neurons or neural networks in the central, peripheral, and neighboring or remote parts of the autonomic nervous system through electrical or chemical effects, thereby improving patients' quality of life or improving body function. The company currently has long-term business in the field of non-implantable neuromodulation
Gelonghui FinanceMar 11 05:20 ET
Weiss Healthcare (688580.SH): Accumulated repurchases of 237,900 shares
Gelonghui, March 1, 丨 Weisi Healthcare (688580.SH) announced that as of February 29, 2024, the company had repurchased a total of 237,893 shares of the company through centralized bidding transactions through the Shanghai Stock Exchange, accounting for 0.3467% of the company's total share capital. The highest price of the repurchase transaction was 65.88 yuan/share, the lowest price was 41.23 yuan/share, and the total amount of capital paid was RMB 13,107,011.20 (excluding transaction fees such as stamp duty and transaction fees).
Gelonghui FinanceMar 1 04:52 ET
No Data
No Data